INCY Incyte Corporation

73.96
-0.36  -0%
Previous Close 74.32
Open 74.74
Price To Book 8.23
Market Cap 15847004417
Shares 214,264,527
Volume 1,689,855
Short Ratio
Av. Daily Volume 1,269,261

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data met primary endpoint - February 4, 2019.
Baricitinib
Atopic dermatitis
Phase 2 interim data at ESMO October 2018. ORR 40%.
INCB54828 (FIGHT-202)
Cholangiocarcinoma
Phase 2 interim data released at ASH 2018.
INCB54828 (FIGHT-203)
MPN (Myeloproliferative Neoplasms)
Phase 2 enrolment to be completed in 2019.
INCB54828 (FIGHT-201)
Bladder cancer
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Phase 1/2 enrolling.
Epacadostat with Keytruda - (ECHO-206)
Cancer - solid tumors
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line non-small cell lung cancer
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line head and neck cancer
Approved November 16, 2011.
Jakafi
Myelofibrosis
Phase 3 data due 2H 2019.
Itacitinib - GRAVITAS-301
Treatment-naïve acute GVHD
Phase 3 trial to be initiated in 2018.
Baricitinib
Psoriatic arthritis
Phase 2 trial to be discontinued - noted June 21, 2018.
INCB50465 (CITADEL-202)
Diffuse large B cell lymphoma
Pivotal Phase 2 trial initiation announced November 15, 2017.
Ruxolitinib (RESET-272)
Essential thrombocythemia
Phase 3 data due 2H 2019.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 data due 2H 2019.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 3 planned.
Epacadostat with Keytruda
Squamous cell carcinoma of the head and neck cancer
Phase 3 planned.
Epacadostat with Keytruda
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
CRL received April 14, 2017. NDA resubmitted. Approval announced for low dose only - June 1, 2018.
Baricitinib
Rheumatoid arthritis
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Approved December 4, 2014.
Jakafi (ruxolitinib) (RESPONSE)
Polycythemia Vera
PDUFA date under priority review extended by three months to May 24, 2019.
Ruxolitinib
Graft versus host disease
Phase 3 trial discontinued due to lack of efficacy
Ruxolitinib - JANUS 1 and JANUS 2
Cancer - Pancreatic
Phase 2 trial stopped January 2016 due to lack of efficacy
Ruxolitinib
Colorectal cancer
Endpoint not met, mid-2014
Jakafi (ruxolitinib) (RELIEF)
Disease-related symptoms in patients with Polycythemia Vera
Phase 3 trial to commence 1H 2018.
Epacadostat with durvalumab
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-303)
Bladder cancer
Phase 2 released October 19, 2018. ORR 72% in treatment-naive patients, 39% in previously treated patients.
INC280
Non-small cell lung cancer
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-307)
Bladder cancer
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-304)
Head & neck cancer
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-309)
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-310)
Head and neck cancer
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-306)
Non-small cell lung cancer (NSCLC)
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-305)
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-302)
Renal cancer
Phase 1 oral abstract June 1, 2018, 2:45p.m. CT. Abstract 8005.
Ruxolitinib, Lenalidomide, and Methylprednisolone
Relapsed/Refractory Multiple Myeloma
Phase 1/2 ongoing.
INCB024360 + Epacadostat
Solid tumors
Phase 3 data due 2020.
Ruxolitinib - TRuE-AD
Atopic dermatitis
Phase 2 initial data due 2020.
Parsaclisib INCB50465 (CITADEL-203)
Follicular lymphoma
Phase 2 initial data due 2020.
Parsaclisib INCB50465 (CITADEL-204)
Marginal zone lymphoma
Phase 2 initial data due 2020.
Parsaclisib INCB50465 (CITADEL-205)
Mantle cell lymphoma
Phase 1 data due 2021.
INCMGA0012
Anal cancer
Phase 1 poster presentation at AACR April 1, 2019.
INCMGA0012
Solid tumors
Phase 1 data due 2020.
INCMGA0012
Endometrial cancer
Phase 1/2 initial data due 2019.
INCB53914 and ruxolitinib
Myelofibrosis and Solid Tumors
Phase 2 data presented at ASH December 2, 2018.
INCB50465 and ruxolitinib
Myelofibrosis
Phase 2 data due 2019.
Ruxolitinib
Vitiligo
Phase 1/2 data due 2H 2019.
INCB001158
Solid tumors
Phase 3 data due 2020.
Baricitinib
Alopecia Areata
Phase 3 data due 2021.
Baricitinib
Systemic lupus erythematosus (SLE)
Phase 3 commencement of dosing announced January 22, 2019.
Itacitinib - GRAVITAS-309
Chronic Graft-Versus-Host Disease